These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21872471)

  • 1. Acetylcholine receptor antibodies in patients with genetic myopathies: clinical and biological significance.
    Lane RJ; Roncaroli F; Charles P; McGonagle DG; Orrell RW
    Neuromuscul Disord; 2012 Feb; 22(2):122-8. PubMed ID: 21872471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of facioscapulohumeral muscular dystrophy and myasthenia gravis with positivity of anti-Ach receptor antibody: a fortuitous association?
    Filippelli E; Barone S; Granata A; Nisticò R; Valentino P
    Neurol Sci; 2019 Jan; 40(1):195-197. PubMed ID: 30215155
    [No Abstract]   [Full Text] [Related]  

  • 3. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients.
    Oshima M; Deitiker PR; Smith RG; Mosier D; Atassi MZ
    Autoimmunity; 2012 Mar; 45(2):153-60. PubMed ID: 21985279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.
    Farrugia ME; Kennett RP; Hilton-Jones D; Newsom-Davis J; Vincent A
    Clin Neurophysiol; 2007 Feb; 118(2):269-77. PubMed ID: 17157556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic challenges in facioscapulohumeral muscular dystrophy.
    Sacconi S; Salviati L; Bourget I; Figarella D; Péréon Y; Lemmers R; van der Maarel S; Desnuelle C
    Neurology; 2006 Oct; 67(8):1464-6. PubMed ID: 17060574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
    Higuchi O; Hamuro J; Motomura M; Yamanashi Y
    Ann Neurol; 2011 Feb; 69(2):418-22. PubMed ID: 21387385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thymectomy and muscle antibodies in myasthenia gravis].
    Romi F; Gilhus NE; Aarli JA
    Tidsskr Nor Laegeforen; 2004 Mar; 124(5):629-31. PubMed ID: 15004605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Facioscapulohumeral muscular dystrophy. The spectrum of clinical manifestations and molecular genetic changes].
    Krasnianski M; Neudecker S; Eger K; Schulte-Mattler W; Zierz S
    Nervenarzt; 2003 Feb; 74(2):151-8. PubMed ID: 12596016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myasthenia gravis induced by autoantibodies against MuSK].
    Shigemoto K; Konishi T; Ohta M
    Nihon Rinsho; 2008 Jun; 66(6):1149-54. PubMed ID: 18540361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor.
    Vernet-der Garabedian B; Lacokova M; Eymard B; Morel E; Faltin M; Zajac J; Sadovsky O; Dommergues M; Tripon P; Bach JF
    J Clin Invest; 1994 Aug; 94(2):555-9. PubMed ID: 8040310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenic mechanisms of myasthenia gravis induced by antibodies against muscle-specific kinase].
    Maruyama N; Shigemoto K
    Rinsho Shinkeigaku; 2007 Nov; 47(11):842-4. PubMed ID: 18210813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-AChR-negative myasthenia gravis: clinical and immunological features.
    Evoli A; Bartoccioni E; Batocchi AP; Scuderi F; Tonali P
    Clin Invest Med; 1989 Apr; 12(2):104-9. PubMed ID: 2706833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor.
    Maggi L; Andreetta F; Antozzi C; Confalonieri P; Cornelio F; Scaioli V; Mantegazza R
    Neuromuscul Disord; 2008 Aug; 18(8):678-80. PubMed ID: 18657424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
    Baggi F; Antozzi C; Toscani C; Cordiglieri C
    Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.